^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Archer® FusionPlex® Comprehensive Thyroid & Lung (CTL) Kit

    Company:
    Integrated DNA Technologies
    Type:
    Laboratory Developed Test
    Related tests:
    Evidence Level:
    Resistant: C4 – Case Studies

    [PD-L1 overexpression + RET-KIF5B fusion-Non Small Cell Lung Cancer-pembrolizumab]

    Source:
    J Clin Med
    Test:

    PD-L1 IHC 22C3 pharmDx, Archer® FusionPlex® Comprehensive Thyroid & Lung (CTL) Kit

    Title:
    Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
    Published date:
    03/15/2022
    Excerpt:
    ...we present two cases of RET-rearranged NSCLC patients with high PD-L1 expression (>50%), treated with pembrolizumab within routine clinical practice....A 65-year-old woman...diagnosis of adenocarcinoma with 70% of PD-L1 TPS...Molecular testing confirmed CCDC6-RET fusion...pembrolizumab treatment was initiated in February 2020. Progressive disease (mediastinal lymph nodes progression, new lung nodules, bone lesions, and liver metastases) was found on CT which was performed three months later in May 2020—the patient received four doses of pembrolizumab (200 mg i.v. every 21 days) (Figure 4). Then, palliative chest radiotherapy was performed. Afterwards, due to the poor performance status...
    DOI:
    https://doi.org/10.3390/jcm11061630